SNTI vs. PMCB, APTO, EVAX, ZIVO, TVGN, AIM, COEP, BCLI, CHRO, and GENE
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), Evaxion Biotech A/S (EVAX), ZIVO Bioscience (ZIVO), Tevogen Bio (TVGN), AIM ImmunoTech (AIM), Coeptis Therapeutics (COEP), Brainstorm Cell Therapeutics (BCLI), Chromocell Therapeutics (CHRO), and Genetic Technologies (GENE). These companies are all part of the "biological products, except diagnostic" industry.
Senti Biosciences (NASDAQ:SNTI) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.
PharmaCyte Biotech has lower revenue, but higher earnings than Senti Biosciences. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Senti Biosciences received 3 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
In the previous week, Senti Biosciences had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for PharmaCyte Biotech. Senti Biosciences' average media sentiment score of 0.00 equaled PharmaCyte Biotech'saverage media sentiment score.
PharmaCyte Biotech has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. PharmaCyte Biotech's return on equity of -9.69% beat Senti Biosciences' return on equity.
25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are owned by institutional investors. 12.5% of Senti Biosciences shares are owned by insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Senti Biosciences has a beta of 2.88, indicating that its share price is 188% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.
Senti Biosciences presently has a consensus price target of $6.00, suggesting a potential upside of 1,470.68%. Given Senti Biosciences' higher possible upside, equities research analysts clearly believe Senti Biosciences is more favorable than PharmaCyte Biotech.
Summary
Senti Biosciences beats PharmaCyte Biotech on 8 of the 14 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
